NCT05789069 - A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Renal Cell CarcinomaMelanomaNon Small Cell Lung CancerGastric CancerColorectal Cancer

Interventions

DRUG

HFB200603

Participants will be administered HFB200603 as described in the experimental arm.

DRUG

Tislelizumab

Participants will be administered tislelizumab as described in the experimental arm.

Trial Locations (11)

19111

TERMINATED

Fox Chase Cancer Center, Philadelphia

22031

TERMINATED

New Experimental Therapeutics of Virginia - NEXT Oncology, Fairfax

28027

RECRUITING

Clinica Universidad de Navarra - Madrid, Madrid

28040

RECRUITING

South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz, Madrid

28050

RECRUITING

South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC, Madrid

31008

RECRUITING

Clinica Universidad de Navarra - Pamplona, Pamplona

37134

RECRUITING

Centro Ricerche Cliniche di Verona s.r.l., Verona

46010

RECRUITING

Hospital Clinico Universitario de Valencia, Valencia

80131

TERMINATED

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli

90033

RECRUITING

USC Norris Comprehensive Cancer Center, Los Angeles

00168

RECRUITING

UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome